Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Grard, Soazic, Catho, Gaud, Valour, Florent, Bouaziz, Anissa, Perpoint, Thomas, Braun, Evelyne, Biron, François, Miailhes, Patrick, Ferry, Tristan, Chidiac, Christian, Souquet, Pierre-Jean, Couraud, Sébastien, Lina, Gérard, Goutelle, Sylvain, Veziris, Nicolas, Dumitrescu, Oana, Ader, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690547/
https://www.ncbi.nlm.nih.gov/pubmed/26719846
http://dx.doi.org/10.1093/ofid/ofv175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690547/
https://www.ncbi.nlm.nih.gov/pubmed/26719846
http://dx.doi.org/10.1093/ofid/ofv175

Ejemplares similares